Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Ruddy

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Cancer Immunology Research|November 12, 2020
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody TherapySi-Qi Liu, Alyssa Grantham, Casey Landry, et al.
Molecular Cancer Research : MCR|November 20, 2021
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid LeukemiaFlorencia Rago, Lindsey Ulkus Rodrigues, Megan Bonney, et al.
Cancer Discovery|July 12, 2013
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Manav Korpal, Joshua M Korn, Xueliang Gao, et al.
Genetics|January 18, 2006
Presenilin-based genetic screens in Drosophila melanogaster identify novel notch pathway modifiersMatt B Mahoney, Annette L Parks, David A Ruddy, et al.
Developmental Cell|July 12, 2002
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulationRoss Francis, Garth McGrath, Jianhuan Zhang, et al.
Oncotarget|March 28, 2020
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathwayCaroline Dafflon, Swann Gaulis, Louise Barys, et al.
Cancer Research|January 28, 2021
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal MicroenvironmentHui Qin Wang, Iain J Mulford, Fiona Sharp, et al.
Nature Medicine|December 19, 2018
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR lossHuayang Liu, Javad Golji, Lauren K Brodeur, et al.
Nature Cancer|January 17, 2024
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomasAhmed M O Elbatsh, Ali Amin-Mansour, Anne Haberkorn, et al.
Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Cancer Immunology Research|November 12, 2020
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody TherapySi-Qi Liu, Alyssa Grantham, Casey Landry, et al.
Molecular Cancer Research : MCR|November 20, 2021
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid LeukemiaFlorencia Rago, Lindsey Ulkus Rodrigues, Megan Bonney, et al.
Cancer Discovery|July 12, 2013
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Manav Korpal, Joshua M Korn, Xueliang Gao, et al.
Genetics|January 18, 2006
Presenilin-based genetic screens in Drosophila melanogaster identify novel notch pathway modifiersMatt B Mahoney, Annette L Parks, David A Ruddy, et al.
Developmental Cell|July 12, 2002
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulationRoss Francis, Garth McGrath, Jianhuan Zhang, et al.
Oncotarget|March 28, 2020
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathwayCaroline Dafflon, Swann Gaulis, Louise Barys, et al.
Cancer Research|January 28, 2021
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal MicroenvironmentHui Qin Wang, Iain J Mulford, Fiona Sharp, et al.
Nature Medicine|December 19, 2018
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR lossHuayang Liu, Javad Golji, Lauren K Brodeur, et al.
Nature Cancer|January 17, 2024
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomasAhmed M O Elbatsh, Ali Amin-Mansour, Anne Haberkorn, et al.
Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.
Pageof 4